查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593025

鼻腔給藥市場：依產品、劑量、應用、通路 - 2025-2030 年全球預測

Intranasal Drug & Vaccine Delivery Market by Product (Liquid Delivery Device, Powder Delivery Device, Pressurized Metered Dose Inhaler), Dosage (Multi-Dose, Unit-Dose), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年鼻腔給藥市值為518.9億美元，預計2024年將達到558.8億美元，複合年成長率為8.17%，預計到2030年將達到899.3億美元。

鼻腔藥物傳遞和經鼻吸入型疫苗遞送涉及透過鼻腔施用治療劑並利用富含血管的鼻上皮來快速吸收。這種需求是因為它的非侵入性、改善的患者依從性，特別是效用在繞過胃腸道和初級代謝、提高蛋白質、勝胜肽和疫苗的生物有效性的有用性。應用範圍廣泛，包括過敏性鼻炎、偏頭痛、骨質疏鬆症和疫苗輸送，特別是 COVID-19 疫苗的最新進展。最終用途細分包括醫院、診所和居家醫療機構，越來越偏好自我管理治療。關鍵的市場成長要素包括配方技術和輸送設備的技術進步、積極的監管前景以及需要非侵入性輸送系統的慢性疾病盛行率的增加。新的商機在於消費者對無針藥物替代品不斷成長的需求，以及對中樞神經系統疾病和大流行病預防的創新鼻製劑研發的大量投資。儘管有這些前景，挑戰仍然存在，包括藥物滲透性、黏膜清除以及鼻腔給藥藥物潛在的局部刺激。監管複雜性和高昂的開發成本進一步阻礙了市場的穩定發展。為了克服這些問題，有一些成熟的創新領域，包括黏合聚合物的增強、奈米載體系統，以及具有最佳化穩定性和生物有效性的控制釋放特性的新型裝置。生物技術公司和研究機構之間的聯合舉措可以加速針對阿茲海默症、帕金森氏症和腸溶製劑的藥物開發。鼻腔給藥市場的特點是競爭激烈且創新，需要結合製藥專業知識和尖端技術的策略聯盟。隨著公司在這一發展中領域的發展，將研發重點放在未滿足的市場需求上並探索監管途徑似乎可以解決現有的市場障礙，同時抓住新的機會。

主要市場統計
基準年[2023] 518.9億美元
預測年份 [2024] 558.8億美元
預測年份 [2030] 899.3億美元
複合年成長率（%） 8.17%

市場動態：揭示快速發展的鼻腔給藥市場的關鍵市場洞察

供需的動態交互作用正在改變鼻腔給藥市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 呼吸系統和神經系統疾病的盛行率上升
    • 供應鏈網路擴張與商業化
    • 非侵入性給藥途徑處方增加
  • 市場限制因素
    • 與鼻腔給藥相關的副作用
  • 市場機會
    • 新興經濟體改善醫療基礎設施和先進治療的潛力
    • 鼻腔給藥系統相關技術的進步
  • 市場挑戰
    • 開發問題，例如疫苗需要大劑量以及難以透過鼻腔途徑給藥

波特五力：駕馭鼻腔給藥市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更具彈性的市場定位。

PESTLE分析：了解對鼻腔給藥市場的外部影響

外部宏觀環境因素在塑造鼻腔給藥市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解鼻腔給藥市場的競爭狀況

鼻腔給藥市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣鼻給藥市場供應商的績效評估

FPNV 定位矩陣是評估鼻腔給藥市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製鼻腔給藥市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，鼻腔給藥市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 呼吸系統和神經系統疾病的盛行率增加
      • 供應鏈網路擴張與商業化
      • 非侵入性給藥途徑的處方數量不斷增加
    • 抑制因素
      • 與鼻腔給藥相關的副作用
    • 機會
      • 改善新興經濟體的醫療基礎設施並提供先進的治療方法
      • 鼻腔給藥系統的技術進步
    • 任務
      • 疫苗需要大劑量、鼻內給藥困難等發展挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章鼻腔給藥市場：依產品

  • 供液裝置
  • 送粉裝置
  • 加壓定量吸入器

第7章鼻腔給藥市場（按劑量）

  • 多劑量
  • 單位劑量

第8章鼻腔給藥市場：依應用分類

  • 神經系統疾病
  • 疼痛管理
  • 呼吸系統疾病
  • 疫苗接種

第9章鼻腔給藥市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章北美及南美鼻腔給藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區鼻腔給藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲鼻腔給藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 3M Company
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Becton, Dickinson, and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Marina Biotech, Inc.
  • Merck & Co., Inc.
  • Neurelis Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A339DAEFA961

The Intranasal Drug & Vaccine Delivery Market was valued at USD 51.89 billion in 2023, expected to reach USD 55.88 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 89.93 billion by 2030.

The scope of intranasal drug and vaccine delivery involves administering therapeutics through the nasal cavity, leveraging the highly vascularized nasal epithelium for rapid absorption. Its necessity stems from the non-invasive nature, improved patient compliance, and particularly its utility in bypassing the gastrointestinal tract and first-pass metabolism, enhancing bioavailability of proteins, peptides, and vaccines. Applications are diverse, spanning allergic rhinitis, migraine, osteoporosis, and notably vaccine delivery with recent advancements in COVID-19 vaccines. End-use segmentation includes hospitals, clinics, and home care settings, with increasing preference for self-administered treatments. Key market growth factors involve technological advancements in formulation techniques and delivery devices, positive regulatory outlooks, and a growing prevalence of chronic diseases that demand non-invasive delivery systems. Emerging opportunities lie in the rising consumer demand for needle-free alternatives and significant investments in R&D for innovative nasal formulations that address central nervous system disorders and pandemic preparedness. Despite these prospects, challenges loom in the form of limited drug permeation, mucociliary clearance, and the nasally administered agent's potential local irritation. Regulatory complexities and high development costs further impede steady market progress. To overcome these, areas ripe for innovation include enhanced mucoadhesive polymers, nanocarrier systems, and novel devices with controlled release properties that optimize stability and bioavailability. Collaborative initiatives between biotech firms and research institutions can accelerate the development of drugs targeting Alzheimer's, Parkinson's, and enteric-coated formulations for improved targeting. The intranasal delivery market is characterized by a competitive yet innovative landscape, demanding strategic alliances to combine medicinal expertise with advanced technology. As businesses navigate this evolving sector, aligning R&D focus with market unmet needs and advancing regulatory pathways could seize emerging opportunities while addressing existing market barriers.

KEY MARKET STATISTICS
Base Year [2023] USD 51.89 billion
Estimated Year [2024] USD 55.88 billion
Forecast Year [2030] USD 89.93 billion
CAGR (%) 8.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intranasal Drug & Vaccine Delivery Market

The Intranasal Drug & Vaccine Delivery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of respiratory and neurological diseases
    • Expansion of supply chain networks and commercialization
    • Rise in number of prescriptions for non-invasive drug delivery routes
  • Market Restraints
    • Side effects associated with the use of nasal routes
  • Market Opportunities
    • Improving healthcare infrastructure and advanced treatment availability in developing economies
    • Technological advancements related to nasal drug delivery systems
  • Market Challenges
    • Development challenges such as requirements of large dose of vaccine and administration difficulties through the nasal route

Porter's Five Forces: A Strategic Tool for Navigating the Intranasal Drug & Vaccine Delivery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intranasal Drug & Vaccine Delivery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intranasal Drug & Vaccine Delivery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intranasal Drug & Vaccine Delivery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intranasal Drug & Vaccine Delivery Market

A detailed market share analysis in the Intranasal Drug & Vaccine Delivery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intranasal Drug & Vaccine Delivery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intranasal Drug & Vaccine Delivery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intranasal Drug & Vaccine Delivery Market

A strategic analysis of the Intranasal Drug & Vaccine Delivery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intranasal Drug & Vaccine Delivery Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AstraZeneca PLC, Bausch Health Companies Inc., Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Marina Biotech, Inc., Merck & Co., Inc., Neurelis Inc., Novartis AG, OptiNose, Inc., Pfizer Inc., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Intranasal Drug & Vaccine Delivery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Liquid Delivery Device, Powder Delivery Device, and Pressurized Metered Dose Inhaler.
  • Based on Dosage, market is studied across Multi-Dose and Unit-Dose.
  • Based on Application, market is studied across Neurological Disorders, Pain Management, Respiratory Disorders, and Vaccination.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of respiratory and neurological diseases
      • 5.1.1.2. Expansion of supply chain networks and commercialization
      • 5.1.1.3. Rise in number of prescriptions for non-invasive drug delivery routes
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the use of nasal routes
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving healthcare infrastructure and advanced treatment availability in developing economies
      • 5.1.3.2. Technological advancements related to nasal drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Development challenges such as requirements of large dose of vaccine and administration difficulties through the nasal route
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intranasal Drug & Vaccine Delivery Market, by Product

  • 6.1. Introduction
  • 6.2. Liquid Delivery Device
  • 6.3. Powder Delivery Device
  • 6.4. Pressurized Metered Dose Inhaler

7. Intranasal Drug & Vaccine Delivery Market, by Dosage

  • 7.1. Introduction
  • 7.2. Multi-Dose
  • 7.3. Unit-Dose

8. Intranasal Drug & Vaccine Delivery Market, by Application

  • 8.1. Introduction
  • 8.2. Neurological Disorders
  • 8.3. Pain Management
  • 8.4. Respiratory Disorders
  • 8.5. Vaccination

9. Intranasal Drug & Vaccine Delivery Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Intranasal Drug & Vaccine Delivery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Intranasal Drug & Vaccine Delivery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Intranasal Drug & Vaccine Delivery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. AstraZeneca PLC
  • 3. Bausch Health Companies Inc.
  • 4. Baxter International, Inc.
  • 5. Becton, Dickinson, and Company
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Marina Biotech, Inc.
  • 9. Merck & Co., Inc.
  • 10. Neurelis Inc.
  • 11. Novartis AG
  • 12. OptiNose, Inc.
  • 13. Pfizer Inc.
  • 14. Teleflex Incorporated
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET RESEARCH PROCESS
  • FIGURE 2. INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRANASAL DRUG & VACCINE DELIVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY LIQUID DELIVERY DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY POWDER DELIVERY DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY UNIT-DOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, 2023